- Home
- TDF vs FENC Comparison
TDF vs FENC Comparison
Compare TDF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | FENC |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.0M | 263.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | TDF | FENC |
|---|---|---|
| Price | $11.28 | $7.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 99.1K | ★ 114.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,538,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $8.13 | $4.68 |
| 52 Week High | $12.20 | $9.92 |
Technical Indicators
Market Signals| Indicator | TDF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 47.35 |
| Support Level | $11.29 | $7.40 |
| Resistance Level | $11.42 | $8.09 |
| Average True Range (ATR) | 0.17 | 0.42 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 44.29 | 37.74 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.